Vertiv stock slips premarket as Barclays lifts VRT to Overweight, sets $200 target
2 January 2026
1 min read

Vertiv stock slips premarket as Barclays lifts VRT to Overweight, sets $200 target

NEW YORK, January 2, 2026, 06:40 ET — Premarket

  • Vertiv shares moved lower in early trading as investors weighed a fresh Barclays upgrade against a softer tech backdrop.
  • Barclays raised its rating to Overweight and increased its one-year price target to $200.
  • Traders are watching whether the bullish call can drive follow-through when regular trading opens.

Vertiv Holdings Co (VRT) shares slipped 1.5% in premarket trading on Friday after a fresh bullish call from Barclays on the data-center infrastructure supplier. The stock was at $162.01 at 6:28 a.m. ET, about $2.40 below its previous close.

The call matters now because investors are resetting positions for 2026 and looking for signals on whether data-center spending is still translating into earnings upgrades. Vertiv has become a closely watched proxy for power and cooling demand tied to higher-density computing.

Analyst ratings can be a near-term catalyst for these shares, particularly around the company’s first full-year outlook for the new calendar year. A “price target” is an analyst’s estimate of where the stock could trade over the next 12 months.

Barclays upgraded Vertiv to Overweight from Equal Weight and raised its one-year target price to $200 from $181, Stocktwits reported, citing TheFly. Barclays analyst Julian Mitchell flagged “substantial upside potential” to current earnings forecasts for 2026 and 2027 and said the company’s initial 2026 revenue and profit outlook should come in above consensus. 1

Even with the upgrade, early trading pointed to caution toward high-momentum industrial technology names. Premarket moves can look outsized when liquidity is thin.

The broader tape also leaned lower: the S&P 500-linked SPDR ETF (SPY) was down 0.7%, while the Nasdaq-tracking Invesco QQQ (QQQ) fell 0.8%. The VanEck Semiconductor ETF (SMH) slipped 0.9%.

AI-linked names were mixed to lower, with Nvidia down 0.5% and power-management group Eaton off 0.7% in premarket trade.

Vertiv provides mission-critical digital infrastructure for data centers and networks, selling power management and thermal management equipment alongside monitoring systems and services, according to a Reuters company profile. 2

Investors have treated the company as a leveraged play on data-center buildouts, where higher server density raises demand for power delivery and cooling. That link can move quickly when analysts focus on guidance and earnings revisions.

The flip side is that the shares can be sensitive to any hint of delayed projects, customer digestion or margin pressure. A weaker risk backdrop in tech can also spill into adjacent infrastructure names.

Traders will look for follow-through after the opening bell and for more commentary on 2026 expectations in coming weeks. The next major checkpoint is Vertiv’s next quarterly update, when investors will focus on its initial full-year outlook, order trends and cash generation.

Stock Market Today

NASA’s SPHEREx spots interstellar comet 3I/ATLAS flaring on its way out — and the chemistry surprised scientists

NASA’s SPHEREx spots interstellar comet 3I/ATLAS flaring on its way out — and the chemistry surprised scientists

7 February 2026
NASA’s SPHEREx telescope detected interstellar comet 3I/ATLAS sharply brightening in December 2025 as it left the solar system, with infrared data revealing a surge of gas and dust, including water vapor and organic molecules. The comet, only the third confirmed interstellar object, passed no closer than 1.8 astronomical units from Earth. China’s Tianwen-1 Mars orbiter also captured images of the comet.
AstraZeneca stock price: What could move AZN next week as earnings loom

AstraZeneca stock price: What could move AZN next week as earnings loom

7 February 2026
AstraZeneca shares rose Friday, closing at $193.03 in New York, up 3.1%, and 14,104p in London, up 0.9%. The company reports full-year and Q4 2025 results Tuesday, with investors focused on 2026 guidance. The FDA this week issued a complete response letter for a subcutaneous Saphnelo filing, while granting Priority Review to Datroway for breast cancer. AstraZeneca recently shifted its primary U.S. listing to the NYSE.
Rolls-Royce stock rises in London as defence shares lead the first trading day of 2026
Previous Story

Rolls-Royce stock rises in London as defence shares lead the first trading day of 2026

Rocket Lab (RKLB) stock rises in premarket as Space Force satellite deal stays in focus
Next Story

Rocket Lab (RKLB) stock rises in premarket as Space Force satellite deal stays in focus

Go toTop